NCT00676260View on ClinicalTrials.gov

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

August 31, 2004

Conditions
Diabetes Mellitus
Interventions
DRUG

Pioglitazone

Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks

DRUG

Placebo

Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks

Trial Locations (1)

Unknown

Exeter

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT00676260 - Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin | Biotech Hunter | Biotech Hunter